Antitumor Activity of the Investigational Proteasome Inhibitor MLN9708 in Mouse Models of B-cell and Plasma Cell Malignancies-Reference-Cited by-同舟云学术

Antitumor Activity of the Investigational Proteasome Inhibitor MLN9708 in Mouse Models of B-cell and Plasma Cell Malignancies

Published:2011-09-08 Issue:23 Volume:17 Page:7313-7323
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Lee Edmund C.,Fitzgerald Michael,Bannerman Bret,Donelan Jill,Bano Kristen,Terkelsen Jennifer,Bradley Daniel P.,Subakan Ozlem,Silva Matthew D.,Liu Ray,Pickard Michael,Li Zhi,Tayber Olga,Li Ping,Hales Paul,Carsillo Mary,Neppalli Vishala T.,Berger Allison J.,Kupperman Erik,Manfredi Mark,Bolen Joseph B.,Van Ness Brian,Janz Siegfried

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 97 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In vivo activity of the second-generation proteasome inhibitor ixazomib against pediatric T-cell acute lymphoblastic leukemia xenografts;Experimental Hematology;2024-04

2. Antitumor activity of alkylphospholipid edelfosine in prostate cancer models and endoplasmic reticulum targeting;Biomedicine & Pharmacotherapy;2023-11

3. RNF126, 168 and CUL1: The Potential Utilization of Multi-Functional E3 Ubiquitin Ligases in Genome Maintenance for Cancer Therapy;Biomedicines;2023-09-13

4. Relaps Refrakter Multiple Myelomda Iksazomib, Lenalidomid, Deksametazon Kombinasyonu Deneyimi: Gerçek Yaşam Verisi;Uludağ Üniversitesi Tıp Fakültesi Dergisi;2023-06-09

5. Real-world data on the effectiveness and safety of Ixazomib-Lenalidomide-Dexamethasone therapy in relapsed/refractory multiple myeloma patients: a multicenter experience in Turkey;Journal of Chemotherapy;2023-05-21